Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic Pens Drug-Repositioning Deal With Roche; Stands to Pocket Royalties, Milestones

NEW YORK, Dec. 8 (GenomeWeb News) - Gene Logic has penned a "drug-repositioning" alliance with Roche in an effort to help the Swiss drug giant identify alternative development paths for "multiple" candidate compounds, the company said today.

 

The Roche drugs Gene Logic will reevaluate under its Drug Repositioning Program have all passed Phase I human trials but were discontinued in Phase II or Phase III trials.

Gene Logic stands to receive success-based milestone payments for each drug candidate Roche returns to clinical development, and could pocket royalties for each marketed drug, the company said.

 

The agreement also gives Gene Logic the option to receive an exclusive license to any drug candidate that Roche chooses not to pursue. In this case, Roche, not Gene Logic, will receive success-based milestone and royalties.

The news comes three months after Gene Logic said it would help Pfizer, the world's biggest drug maker by revenue, reposition its stalled candidates.

Gene Logic's Drug Repositioning Program, which the company outlined in March, aims to find alternative development paths for drug candidates with good safety records that have been shelved by drug makers in Phase II or Phase III clinical trials.

 

Gene Logic said it can complete "initial repositioning testing and analysis" in less than a year and "potentially" return drug candidates "expediently" to clinical testing.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.